Home
>
US Stocks
>
FibroGen Inc
FibroGen Inc
FGEN

FibroGen Inc

$10.865.15%

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open
10.93
Today Low/High
10.74 / 10.93
52 Week Low/High
$11.75 / $57.21
P/E ratio
-4.7918
Market Cap
$1.11B

Company Details

FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics. The Company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to advance innovative medicines for the treatment of unmet needs. The Company is currently developing and commercializing roxadustat, an oral small molecule inhibitor of HIF prolyl hydroxylase activity, for anemia associated with chronic kidney disease (CKD). Roxadustat is also in clinical development for anemia associated with myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia (CIA). Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical development for the treatment of locally advanced unresectable pancreatic cancer (LAPC), Duchenne muscular dystrophy (DMD), and idiopathic pulmonary fibrosis (IPF).
Organisation
FibroGen Inc
Headquaters
San Francisco, California, US
Employees
599
Industry
Health Technology
CEO
Enrique Conterno

Discover more

Frequently Asked Questions

What is FibroGen Inc share price today

Can Indians buy FibroGen Inc shares?

How can I buy FibroGen Inc shares from India?

Can Fractional shares of FibroGen Inc be purchased?

What are the documents required to start investing in FibroGen Inc stocks?

We are a SEBI registered investement advisor